Patent ID: 6525056
Filing Date: 2003-02-25
Classification: A61P,C07D

Abstract:
A compound of Formula (I) or geometrc isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt forms thereof wherein:Q is selected from the group consisting of: X is N or CR1; Y, Z are independently N or CR2; U, V are independently >C&boxH;G, CR13R14, or NR13, O, or S without forming Oâ€”O, Sâ€”O, or Sâ€”S bonds; G is O or S; R1 is independently at each occurrence â€”H, halogen, â€”CN, C1-C4 haloalkyl, â€”NR9R10, â€”NR9COR9, â€”COR10, â€”OR10, SH or â€”S(O)nR12, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C8 cycloalkylalkyl, where each C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C8 cycloalkylalkyl is each optionally substituted with halogen, â€”CN, C1-C4 haloalkyl, â€”NR9R10, â€”NR9COR9, â€”COR10, â€”OR10, SH or â€”S(O)nR12; R2 is â€”H, halogen, â€”CN, C1-C4 haloalkyl, â€”NR9R10, â€”NR9COR9, â€”COR10, â€”OR10, SH or â€”S(O)nR12, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C7 cycloalkylalkyl, each optionally substituted with halogen, CN, C1-C4 haloalkyl, â€”NR9R10, NR9COR9, â€”COR10, â€”OR10, SH or â€”S(O)nR12; R3 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C10 alkoxyalkyl, C5-C10 cycloalkenyl, C5-C10 cycloalkenylalkyl, where one carbon in any cycloalkyl ring may be replaced with O, S or NR9 and each C1-C10 alkyl, C2-C10 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C10 alkoxyalkyl, C5-C10 cycloalkenyl, C5-C10 cycloalkenylalkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C2-C6 alkenyl, C2-C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, cyano, â€”OR7, SH, â€”S(O)nR11, â€”COR6, â€”NHR6SO2R8, â€”OC(O)NR6R7, â€”N3, â€”OC(O)OR7, â€”CO2R8, â€”OC(O)R6, â€”NR7COR6, â€”N(COR6)2, â€”NR7CONR6R7, â€”NR7CO2R8, â€”NR6R7, â€”CONR6R7, â€”CO2H, aryl, heteroaryl and heterocyclyl or OR3a, NR3aR3b, â€”NHR3a, â€”SOnR3a, â€”SO2NHR3a, â€”SO2NR3aR3b, â€”COR3a, â€”CONHR3a, â€”CONR3aR3b; R3a and R3b are C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C10 alkoxyalkyl, C5-C10 cycloalkenyl, C5-C10 cycloalkenylalkyl, where one carbon in any cycloalkyl may be replaced with O, S or NR9 and each C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C4-C12 cycloalkylalkyl, C2-C10 alkoxyalkyl, C5-C10 cycloalkenyl, C5-C10 cycloalkenylalkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C2-C6 alkenyl, C2-C10 alkynyl, C3-C6 cycloalkyl, halogen, C1-C4 haloalkyl, cyano, â€”OR7, â€”SH, â€”S(O)nR11, â€”COR6, â€”CO2R8, â€”OC(O)R6, â€”NR7COR6, â€”N(COR6)2, â€”NR7CONR6R7, â€”NR7CO2R8, â€”NR6R7, â€”NHR6SO2R8, â€”OC(O)NR6R7, â€”N3, â€”OC(O)OR7, â€”CONR6R7, â€”CO2H, aryl, heteroaryl and heterocyclyl; L is CR42C R42CR42, CR42C R4&boxH;C R4; R4 is independently selected in each occurrence â€”H, â€”OR10, â€”COR9, â€”CO2R8, â€”CONR9R10, â€”CN, â€”NR9R10, â€”S(O)nR12, halogen, C1-C6 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl, wherein C1-C6 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, are optionally substituted with the following functional groups: â€”OR10, â€”COR9, â€”CO2R8, â€”CONR9R10, â€”CN, â€”NR9R10, â€”S(O)nR12, halogen; A1-A4 are independently CR5; R5 is independently at each occurrence â€”H, C1-C10 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, â€”NO2, halogen, â€”CN, â€”NR6R7, â€”NR6COR7, â€”NR6CO2R8, â€”COR6â€”OR7, â€”CONR6R7, â€”CO(NOR9)R11, â€”CO2R8, or â€”S(O)nR11, where C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C6 cycloalkyl and C4-C12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C4 haloalkyl, â€”NO2, halogen, â€”CN, â€”NR6R7, â€”NR6COR7, NR6CO2R8, â€”COR6 â€”OR7, â€”CONR6R7, â€”CO2R8, â€”CO(NOR9)R7, or â€”S(O)nR11 and wherein two adjacent R5 groups can form a 5-7 membered ring saturated on unsaturated optionally containing 1-2 O or SOn or 1-3; N heteroatoms optionally substituted with C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C8 cycloalkylalkyl, C1-C4 haloalkyl, â€”NO2, halogen, â€”CN, â€”NR6R7, â€”NR6COR7, â€”NR6CO2R8, â€”COR6â€”OR7, â€”CONR6R7, â€”CO2R8, â€”CO(NOR9)R7, or â€”S(O)nR11 and not containing any Sâ€”S, Oâ€”O, Sâ€”O or Nâ€”S bonds in the ring; R6 and R7 are independently at each occurrence H, C1-C6 alkyl, C1-C4 haloalkyl, C2-C8 alkoxyalkyl, C3-C6 cycloalkyl, C4-C12 cyclalkylalkyl, C5-C12 bis(alkoxy)alkyl, aryl, aryl(C1-C4 alkyl)â€”, heteroaryl or heteroaryl(C1-C4 alkyl) or NR6R7 is piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine; R8 is independently at each occurrence C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, aryl(C1-C4 alkyl), heteroaryl or heteroaryl(C1-C4 alkyl); R9 and R10 are independently at each occurrence selected from H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkoxyalkyl, C4-C7 cycloalkylalkyl; R11 is independently at each occurrence C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, aryl(C1-C4 alkyl), heteroaryl, heteroaryl(C1-C4 alkyl), or â€”NR6R7; R12 is independently at each occurrence C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl; R13 and R14, are independently at each occurrence H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C12 cycloalkylalkyl, aryl, aryl(C1-C4 alkyl), heteroaryl or heteroaryl(C1-C4 alkyl)â€”, â€”COR12, â€”CO2R8, â€”CONR9, S(O)nR12; aryl is phenyl or naphthyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C4 haloalkyl, cyano, â€”OR10, â€”SH, â€”S(O)nR12, â€”COR12, â€”CO2R8, â€”OC(O)R12, â€”NR9COR9, â€”N(COR12)2, NR9CONR9R10, â€”NR9CO2R8, â€”NR9R10, and â€”CONR9R10; heteroaryl is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzthiazolyl, isoxazolyl , pyrazolyl, triazolyl, tetrazolyl, or indazolyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C4 haloalkyl, cyano, â€”OR10, â€”SH, â€”S(O)nR12, â€”COR12, â€”CO2R8, â€”OC(O)R12, â€”NR9COR9, â€”N(COR12)2, â€”NR9CONR9R10, â€”NR9CO2R8, â€”NR9R10, and â€”CONR9R10; heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 3 substituents independently selected at each occurrence from C1-C6 alkyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C4 haloalkyl, cyano, â€”OR10, SH, â€”S(O)nR12, â€”COR12, â€”CO2R12, â€”OC(O)R12, â€”NR9COR9, â€”N(COR12)2, â€”NR9CONR9R10, â€”NR9CO2R12, â€”NR9R10, and â€”CONR9R10; n is independently at each occurrence 0, 1 or 2 provided that: (a) when Q is Ia, Ib or Ic and X is N, R1 is not H; and (b) R1 is other than O-alkynyl or S-alkynyl.